SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending as traders discuss its potential, citing its low market cap and limited token supply as key factors for possible significant gains. The community is also closely watching for news of a potential partnership with the Truth Network to catalyze further price movement. Recent LinkedIn updates, use cases with Vodafone and Heathrow Airport, and its integration with Polkadot are being highlighted as bullish signals.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid retail-trader buzz fueled by a congressional disclosure of a politician buying shares, sparking speculation of potential government contracts. The community is actively discussing the implications of this purchase, with some drawing comparisons to Palantir and anticipating a breakout due to the company's AI-driven security solutions. Overall sentiment appears bullish, with discussions around chart setups and the potential for a short squeeze.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses Elon Musk's recent $1 billion stock purchase, viewed by some as a sign of confidence and a potential catalyst for further gains. Community members are debating whether this move signals long-term potential or is simply a pump, while also weighing factors like upcoming FSD releases and potential impacts from the Fed. Some traders point to technical indicators and potential resistance levels, while others express concerns about valuation and broader market conditions.

Slopana

Slopana is trending as community members rally around the meme coin, touting its strong community, doxxed leadership, and unique position within the Solana ecosystem. Conversations highlight its availability on Phantom Wallet and potential for significant growth, with some suggesting it could become Solana's mascot. The coin's association with the term 'digital slop' coined by a Solana co-creator is also a key talking point.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

$EDGE.X is trending due to bullish sentiment and community excitement around its potential, with some mentioning a possible listing on Binance. Many traders are actively discussing entry and re-entry points, anticipating a rise to $0.60 and beyond, while also referencing its recent performance relative to other cryptocurrencies like $AVT.X.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders discuss the potential impact of the upcoming Fed meeting and a possible "sell the news" event, with some expressing concerns about the market's overextended state. Community members are debating whether a rate cut is already priced in, and monitoring technical indicators for signs of a potential pullback. Some traders are also noting the potential impact of China-US trade talks.

WEBTOON Entertainment, Inc. engages in the provision of global storytelling platform. The firm offers creators and users to discover, create, and share new content. Its brands include Munpia, Yonder, Studio Lico, LINE, and Creator Studios. The company was founded by Jun-Koo Kim in 2005 and is headquartered in Los Angeles, CA.

Webtoon Entertainment Inc.

Webtoon Entertainment Inc

Webtoon Entertainment ($WBTN) is trending following a surge in after-hours trading, reportedly driven by a deepened partnership with Disney to launch a new digital comics platform. The community is buzzing about the potential of this collaboration, with some highlighting the company's low float and high short interest. Bullish sentiment is fueled by the anticipation of increased revenue and user engagement due to the Disney partnership.

Denny's Corp. engages in the operation of restaurants and franchised, and licensed restaurants. It operates through the Denny's and Other segments. The Denny's segment includes the results of all company and franchised and licensed Denny’s restaurants. The Other segment refers to the results of all company and franchise restaurants. The company was founded by Harold Butler and Richard Jezak in 1953 and is headquartered in Spartanburg, SC.

Denny`s Corp.

DENN is trending amid discussions around its $5 Slams deal and the return of Pumpkin Pecan Pancakes, which are seen as potential traffic drivers. Community members are drawing comparisons to competitors like $CBRL, with some suggesting Denny's is gaining an edge with budget-conscious consumers. Bullish sentiment is fueled by unusual options activity and positive write-ups highlighting the company's digital innovation.

The New York Times Co. is a media organization, which engages in creating, collecting, and distributing news and information. It offers news products and other interest-specific products, and related content and services. It offers newspapers, print, and digital products and investments. The firm also manages The New York Times, NYTimes.com, and mobile applications. The company was founded by Henry Jarvis Raymond and George Jones on September 18, 1851, and is headquartered in New York, NY.

New York Times Co. - Ordinary Shares - Class A

Recent earnings beat estimates, driven by digital subscription growth, is a key catalyst for NYT. Community members are also discussing the potential impact of political events, particularly on media companies. Some are focused on strategic moves like AI licensing agreements and potential acquisitions.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending due to its partnership with Honeywell to develop quantum-secure satellite communication systems backed by the European Space Agency. The community is discussing the potential impact of this deal and the possibility of a short squeeze, while also noting a recent settlement related to past accounting irregularities. Some investors express long-term confidence in RDW's potential in the space sector, despite a recent drop.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the second quarter (Q2), bolstered by payments related to development milestones with both Sanofi and Gilead Sciences.The <a href="https://stocktwits.com/symbol/NRIX">Nurix Therapeutics stock</a> rose 7.9% on Wednesday and climbed another 13.9% after-hours.The company reported a net loss of $0.52 per share for the quarter ended May 31, above analyst estimates of a loss of $0.74 per share.&nbsp;Nurix also recorded revenue of $44.1 million, exceeding estimates of $17.5 million.&nbsp;A large chunk of that came from a $30 million license payment from Sanofi and a $5 million milestone tied to a Gilead-supported clinical program.Spending also increased as the company pushed ahead with its lead drug candidates.&nbsp;Research and development costs climbed to $78.1 million, up from $48.9 million a year earlier, while administrative expenses rose to $14.3 million from $11.7 million.The company shared new data from an early-stage trial of bexobrutideg, a BTK degrader it’s developing for certain blood cancers.&nbsp;Among patients with relapsed or treatment-resistant chronic lymphocytic leukemia, the treatment showed a response rate of 80.9%, with no serious heart issues or other safety red flags reported.Nurix finished the quarter with $485.8 million in cash and investments. The figure doesn’t include an additional $19 million it received shortly after the quarter ended from its partners.Looking ahead, the company plans to start late-stage trials of bexobrutideg later this year.&nbsp;It’s also expecting more clinical updates from other programs in its pipeline, including NX-2127 and NX-1607.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user noted that Nurix’s Q2 loss of $0.52 per share came in about 30% better than analyst expectations, and added that the stock could see another strong session tomorrow.<stembedurl>https://stocktwits.com/LongTrainRunning/message/620401421</stembedurl>Nurix Therapeutics’ stock has declined 32.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix Therapeutics (NRIX) reported stronger-than-expected results for the second quarter/ Photo credit: Getty Images

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 

Equity

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's  What You Should Know

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Unveiling 6 Analyst Insights On Nurix Therapeutics

Latest Ratings for NRIX
 DateFirmActionFromTo Feb 2022Wells FargoInitiates Coverage OnEqual-Weight Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Oct 2021SVB LeerinkMaintainsOutperform...

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase PR Newswire VANCOUVER, BC, Sept. 24...

Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics (NRIX Research Report) today and set a price target of $35.0...

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike PR Newswire VANCOUVER, BC, June 20, 2024 USA News...

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Nurix Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$8.67
Prev Close	$9.04
Open	$9.09
Dividend Yield	0.00%
50-Day Moving Average	$10.72
Beta	1.63
Avg. Volume	669,078.71
PE Ratio	-3.46

52-Week High	$29.56
52-Week Low	$8.18
Market Capitalization	$691.1M
EPS (Annual)	-$2.88
Price to Book	1.54
Revenue Per Employee	$190,730.77
Enterprise Value/EBITDA	N/A

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRIX News

NRIX Nurix Therapeutics Inc